Evidence map›Paper›PMID 38534113›Full record

ArticleAntimicrobial agents and chemotherapy2024

Exploring the links between SOS response, mutagenesis, and resistance during the recovery period.

Sreyashi Ghosh, Mehmet A Orman

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sreyashi GhoshDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA.ORCID 0000-0002-0346-7381
Mehmet A OrmanDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA.ORCID 0000-0001-8499-9154
University of Houston · US

Funding

Characterizing a Self-Digesting-Mediated Reversible Drug Tolerance Mechanism in BacteriaR01AI143643 · NIAID · UNIVERSITY OF HOUSTON · PI ORMAN, MEHMET A. · 2020 to 2024
$1.9M
NIAID NIH HHS R01 AI143643
6 · The paper itself

Abstract

Although the mechanistic connections between SOS-induced mutagenesis and antibiotic resistance are well established, our current understanding of the impact of SOS response levels, recovery durations, and transcription/translation activities on mutagenesis remains relatively limited. In this study, when bacterial cells were exposed to mutagens like ultraviolet light for defined time intervals, a compelling connection between the rate of mutagenesis and the RecA-mediated SOS response levels became evident. Our observations also indicate that mutagenesis primarily occurs during the subsequent recovery phase following the removal of the mutagenic agent. When transcription/translation was inhibited or energy molecules were depleted at the onset of treatment or during the early recovery phase, there was a noticeable decrease in SOS response activation and mutagenesis. However, targeting these processes later in the recovery phase does not have the same effect in reducing mutagenesis, suggesting that the timing of inhibiting transcription/translation or depleting energy molecules is crucial for their efficacy in reducing mutagenesis. Active transcription, translation, and energy availability within the framework of SOS response and DNA repair mechanisms appear to be conserved attributes, supported by their consistent manifestation across diverse conditions, including the use of distinct mutagens such as fluoroquinolones and various bacterial strains.

Indexed as

Escherichia coliMutagenesisRec A RecombinasesSOS Response, GeneticsUltraviolet RaysAnti-Bacterial AgentsDNA RepairDrug Resistance, BacterialEscherichia coli ProteinsMutagensTranscription, GeneticAnti-Bacterial AgentsEscherichia coli ProteinsMutagensRec A Recombinasesantibiotic resistanceDNA repairmutagenesis

Identifiers

PMID38534113
PMCPMC11064565
OpenAlexW4393223918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.